Year: 2025

Amwell set to continue to enable U.S. Defense Health Agency healthcare teams to deliver connected and seamless in-person and virtual care for the Military Health System (“MHS”)

U.S. Defense Health Agency awards Amwell, as part of a Leidos-led Partnership, an extension for the Military Health System’s Digital...

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-endSOUTH SAN FRANCISCO, Calif.,...

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance...

CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement...

GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS’s Fiscal Year 2026

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to...

error: Content is protected !!